Subscribe
shutterstock_1426719905_piotr_swat
Piotr Swat / Shutterstock.com
15 July 2019Big PharmaSaman Javed

Indivior appeal fails to stop generic opioid addiction challenge

The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute
25 August 2020   A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.
Big Pharma
Fed Circ says Indivior patent was anticipated
30 November 2021   The US Court of Appeals for the Federal Circuit has affirmed a US Patent Trial and Appeal Board decision that held that claims of a patent for dissolvable films containing therapeutic agents were anticipated.
Americas
Tribal business settles Stanford opioid treatment clash
29 November 2022   Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute
25 August 2020   A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.
Big Pharma
Fed Circ says Indivior patent was anticipated
30 November 2021   The US Court of Appeals for the Federal Circuit has affirmed a US Patent Trial and Appeal Board decision that held that claims of a patent for dissolvable films containing therapeutic agents were anticipated.
Americas
Tribal business settles Stanford opioid treatment clash
29 November 2022   Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.

More on this story

Americas
Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute
25 August 2020   A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.
Big Pharma
Fed Circ says Indivior patent was anticipated
30 November 2021   The US Court of Appeals for the Federal Circuit has affirmed a US Patent Trial and Appeal Board decision that held that claims of a patent for dissolvable films containing therapeutic agents were anticipated.
Americas
Tribal business settles Stanford opioid treatment clash
29 November 2022   Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent